We need to update the first and third addresses as shown above. Furthermore, “zero” has been modified and replaced by “—” in Table 3.
Table 3.
Efficacy of 61 chemotherapy regimens in 32 patients with measurable disease during first or any subsequent line of therapy.
| N | CR | PR | Overall response (%) | SD | PD | Unknown response (%) |
|
|---|---|---|---|---|---|---|---|
| VA | 6 | — | 1 | 1 (17%) | 5 | — | — |
| IVA | 13 | 3 | 1 | 4 (30%) | 9 | — | — |
| VAC | 3 | — | — | — | 1 | 1 | 1 |
| VAC and tamoxifen | 1 | — | — | — | 1 | — | — |
| Vinblastine-MTX | 14 | — | 7 | 7 (50%) | 5 | 1 | 1 |
| Vinblastine-MTX-tamoxifen | 7 | — | 3 | 3 (43%) | 3 | — | 1 |
| Doxorubicin with other agents* | 5 | — | 2 | 2 (40%) | — | 3 | — |
| Imatinib mesylate | 2 | — | — | — | 2 | — | — |
| Others+ | 10 | — | 2 | 2 (20%) | 1 | 7 | — |
|
| |||||||
| Total | 61 | 3 | 16 | 19 (31%) | 27 (44%) | 12 (20%) | 3 (5%) |
VA: vincristine and dactinomycin; IVA: ifosfamide, vincristine and dactinomycin; VAC: vincristine, dactinomycin, and cyclophosphamide; MTX: methotrexate. N: number of patients; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease.
*Doxorubicin with vincristine, cisplatin, ifosfamide, cyclophosphamide, or tamoxifen.
+Others: VINCAEPI (vincristine, carboplatin, and VM 26), MMT95 protocol (IVA, etoposide, epirubicin, and carboplatin), dactinomycin alone, etoposide-ifosfamide, etoposide alone, and carboplatin.